COVID-19 and UK Biobank: Challenges, Limitations and Future Perspectives

The Coronavirus disease 2019 (COVID-19) pandemic has had a profound impact on health and the way people live globally. Our knowledge of the disease is increasing at a fast pace and thus far has largely been from observational studies and registries, with an increasing number of clinical trials underway assessing treatment options, vaccination and other preventative strategies to limit the morbidity and mortality associated with it.

Overview of the UK Biobank Study—A unique multimodal population study of 500,000 with recent addition of COVID-19 related data.

Large population studies such as the UK Biobank provide great opportunities for understanding the pathophysiology, health impact and prognostic factors associated with COVID-19, a condition that has had a significant impact on almost everyone around the world. This article highlights the vast opportunities, challenges and limitations for research and collaboration from the UK Biobank and other large population studies in helping us better understand and manage both current and potential future pandemics.

Click here to read more.

 

    By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

    The 'OpenSpecimen Biobanking LIMS RFP Q&A' Excel is emailed to you.
    Feel free to Contact Us for any questions.

    Srikanth Adiga,
    C.E.0, OpenSpecimen
    Email: sri@krishagni.com


      Avoid Gmail, Yahoo, etc. please.

      By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        The Features PDF has been emailed to you.
        Feel free to "Schedule a Demo" or "Contact Us" for any questions.

        Srikanth Adiga,
        C.E.0, OpenSpecimen
        Email: sri@krishagni.com

          By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.